In September 2019, the FDA announced that a small amount of cancer-causing chemicals, known as N-Nitrosodimethylamine (NDMA), ...

GSK did not admit wrongdoing as part of the deal, saying in a statement that there was "no consistent or reliable evidence" that ranitidine, the drug's active ingredient, increased the risk of cancer.

In 2019, the Food and Drug Administration said it had detected low levels of a cancer-causing contaminant known as NDMA in samples of Zantac, which at that time was widely sold by prescription and ...

So why would GSK, the largest of the four major distributors of the now-recalled stomach acid drug, suddenly abandon the tried-and-true defense mantra, “millions for defense, not a penny for tribute”?

GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits that alleged its discontinued heartburn drug Zantac caused cancer.

Emma Walmsley, the CEO of GSK, may finally see relief from a major headache caused by legal cases surrounding the now-discontinued heartburn drug Zantac. The update has reignited investor confidence.

The British drugmaker’s settlement with 10 separate law firms resolves 93% of all U.S. cases currently filed against GSK over claims its popular Zantac drug contained the carcinogen N ...

In July, a Delaware judge dismissed a request from GSK and other pharmaceutical companies to appeal a ruling that allows over 70,000 lawsuits alleging the heartburn drug Zantac causes cancer to ...

GSK is on track to achieve its guidance for 2024, with its Q3 2024 and 9m 2024 results today. Explore more details here.